DGX

DGX

USD

Quest Diagnostics Incorporated Common Stock

$178.030-1.320 (-0.736%)

Echtzeitkurs

Healthcare
Diagnostics & Research
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$179.350

Hoch

$180.040

Tief

$176.310

Volumen

0.20M

Unternehmensfundamentaldaten

Marktkapitalisierung

19.8B

Branche

Diagnostics & Research

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.90M

Börse

NYQ

Währung

USD

52-Wochen-Spanne

Tief $148.7Aktuell $178.030Hoch $197.55

Ähnliche Nachrichten

PR Newswire

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients,...

Mehr anzeigen
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Analyst Upgrades

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195

Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $190 to $195.

Mehr anzeigen
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
Analyst Upgrades

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205

Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $195 to $205.

Mehr anzeigen
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
Analyst Upgrades

Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics with a Outperform and raises the price target from $203 to $210.

Mehr anzeigen
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
PR Newswire

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third...

Mehr anzeigen
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics with a In-Line and raises the price target from $185 to $190.

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.